Posts Tagged ‘European Patent’

ASX Company News: Environmental Clean Technology Secures European Patent

Tuesday, October 9th, 2012

Environmental Clean Technologies Limited (ESI) is pleased to advise that it is in receipt of notification that its European Patent application has now been issued as a formal patent, no. 1680637., following  on from the successful granting of Patent coverage for its Coldry technology in the United States and Australia. With the patent now granted, commercial deployment into key EU countries can take place with increased confidence, following commercial demonstration here in Australia.

Chief Operating Officer Ashley Moore commented, “Europe is the world’s highest lignite utilising region, with the top five lignite using countries in the EU accounting for an annual consumption of 395 million tonnes according to the European Association for Coal & Lignite. This highlights the magnitude of the EU market when compared with Australia’s 65-70 million tonnes a year usage. Our progress with the Design for Tender program, the Commercial Demonstration Plant program, and the newly announced Federal & State Government Advanced Lignite Demonstration Program dovetails nicely with EU market conditions.”

ECT is in the business of commercialising leading-edge coal and iron making technologies, which are capable of delivering financial and environmental benefits. We are focused on advancing a portfolio of technologies, which have significant market potential globally. ECT’s business plan is to pragmatically commercialise these technologies and secure sustainable, profitable income streams through licencing and other commercial mechanisms. The MATMOR process has the potential to revolutionise primary iron making. MATMOR is a simple, low cost, low emission, production technology, utilising the patented MATMOR retort, which enables the use of cheaper feedstocks to produce primary iron.

www.ectltd.com.au

Post to Twitter

ASX Company News: Living Cell Technologies Granted European Patent

Wednesday, February 29th, 2012

Living Cell Technologies Limited (LCT)  received formal notification that it has been granted E.U. Patent No. 1,438,395 from the European Patent Office (EPO). The patent protects the ability to culture two different types of cells derived from Auckland Island pigs, therefore enabling the assembly and maintenance of a mix of cells or artificial tissue in culture for xenotransplantation therapies.

Professor Bob Elliott, LCT’s Medical Director said, “Whilst we have successfully taken single cell animal transplant treatments into the clinic, a number of chronic disease states could benefit from transplantation of a mix of cells or artificial tissue that work together to ensure survival and appropriate function.”

The patent will be assigned to Diatranz Otsuka Limited (DOL), a joint venture company established by LCT and Otsuka Pharmaceutical Factory, Inc. to commercialise xenotransplantation for the treatment of Type 1 diabetes. LCT has a 50 per cent shareholding in DOL, and a service agreement to supply research and development and administrative services to the joint venture. Under the Services and Products agreement, DOL will supply pig cells to LCT for use in developing new xenotransplantation treatments in non-diabetes related disease areas, including neurodegenerative disorders.

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company holds 50% of Diatranz Otsuka Limited which owns a bio- certified pig herd that it uses as a source of cells and DIABECELL® which is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. Using breakthrough proprietary microencapsulation technology, IMMUPELTM, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson’s disease, Huntington’s disease, stroke, and hearing loss. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

www.lctglobal.com

http://www.traderdealer.com.au/fundamentals/lct

Post to Twitter

ASX Company News: Anteo Diagnostics Awarded European Patent

Thursday, March 10th, 2011

Anteo Diagnostics Limited (ADO) is pleased to announce that the European Patent Office has issued confirmation that it intends to grant the “Generation of Surface Coating Diversity” patent to the Company. This means that a patent will shortly be granted to Anteo to protect the intellectual property that led to the discovery of the Mix&GoTM technology.

This ensures that the process that was used to bind antibodies to more than 8,000 different types of surfaces cannot be copied in the European market. Also, additional screening exercises that could be initiated to identify new “glues” for a broad range of other industries and sectors will also be covered under this patent which has a 12-year life. The patent was filed in 2003, and given a 20-year life, is due to expire in 2023. The patent has already been granted in Australia and Anteo is currently waiting on it being granted in additional markets.

Anteo’s Managing Director Dr. Geoff Cumming said: “This is a very pleasing and important development for the company, and it underpins the value of the intellectual property that led to the discovery of our Mix&GoTM technology.

www.anteodx.com

http://www.traderdealer.com.au/Fundamentals/ado

Post to Twitter

NuSep Granted European Patent

Tuesday, March 9th, 2010

NuSep (NSP) is pleased to announce that the European patent for the SpermSep has now been granted. This is an important step in the commercial development of the SpermSep as it gives NuSep exclusive rights to manufacture and sell the SpermSep in Europe. NuSep now has granted SpermSep patents in both Australia and Europe.

Sperm separation is a fundamental requirement for all Assisted Reproductive Technology (ART) treatments and the use of ART is growing rapidly as couples plan to have babies into their 30s and 40s when natural fertility begins to decline. In Australia the IVF market is worth around $170m and in the US it is a $3 billion market. The SpermSep instrument addresses approximately 1-2% of these markets. In the 2006 report by the International Committee for Monitoring the Assisted Reproductive Technologies (ICMART) the total number of ART cycles undertaken in the world was estimated at 1 million a year. Based on this, NuSep estimates the total current SpermSep consumables market at $A45m per annum. A number of developments have occurred over the last few months including the development of a disposable cartridge to eliminate contact between the instrument and the sample.

NuSep (NSP) is a publicly listed life sciences company that sells products into the global  BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function. The company has offices in both Sydney Australia and Atlanta, USA. With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification. NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

www.NuSep.com

Post to Twitter